Denmark’s benchmark equity index closed higher on Tuesday, with the OMX Copenhagen 20 rising 1.29% to a one-month peak, as gains in pharmaceuticals and biotechnology offset weakness in shipping and industrial enzymes.
Advancing issues outnumbered decliners 66 to 50 on the Copenhagen Stock Exchange, with 20 stocks unchanged. The index’s gain extended its recent upward trend, reflecting broad-based strength across key sectors.
Pharmaceutical company Zealand Pharma led gains, climbing 5.66% to 326.90 Danish kroner, while biotech firm Genmab added 3.98% to close at 2,196.00 kroner. Energy group Ørsted rose 3.06% to 139.60 kroner.
Declines were led by Novozymes, which fell 1.84% to 448.00 kroner, and shipping giant A.P. Moller - Maersk, whose Class B shares declined 1.52% to 22,090.00 kroner and Class A shares dropped 1.39% to 21,240.00 kroner.
Commodity markets showed broad weakness, with October WTI crude oil futures down 3.14% at $82.34 per barrel and November Brent crude falling 3.08% to $87.75 per barrel. December gold futures slipped 0.02% to $4,696.76 per troy ounce.
The Danish krone held steady against major currencies, with the USD/DKK exchange rate flat at 6.41 and EUR/DKK unchanged at 7.48. The U.S. Dollar Index futures were down 0.03% at 98.90.
